Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL25415664 | 0.77 | HSD17B2 (0.37) | PTGDR2GRM5HSD17B2 | |
| SCHEMBL11223381 | 0.74 | KCNH2 (0.48) | KCNH2PTGDR2GRM5HSD17B2FFAR1 | |
| SCHEMBL30707788 | 0.73 | KCNH2 (0.61) | KCNH2PTGDR2GRM5FFAR1LMNA | |
| SCHEMBL4448140 | 0.73 | KCNH2 (0.61) | KCNH2PTGDR2GRM5FFAR1LMNA | |
| Bromide SCHEMBL25416864 | 0.73 | KCNH2 (0.38) | KCNH2GRM5LMNATSHR | |
| Bromide SCHEMBL17048143 | 0.73 | APP (0.50) | KCNH2GRM5LMNATSHR | |
| SCHEMBL29868474 | 0.69 | KCNH2 (0.52) | KCNH2PTGDR2GRM5FFAR1LMNA | |
| SCHEMBL31279173 | 0.69 | FFAR1 (0.57) | KCNH2PTGDR2GRM5FFAR1LMNA | |
| SCHEMBL1920654 | 0.69 | FFAR1 (0.57) | KCNH2PTGDR2GRM5FFAR1LMNA | |
| SCHEMBL11226493 | 0.68 | KCNH2 (0.43) | KCNH2PTGDR2GRM5HSD17B2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | THE WISTAR INST (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | HSPA2, HSPBP1, HSP90AB1 | KCNH2 4743/4885PTGDR2 3732/4885GRM5 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.